Clinical Trial Update: An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 randomized trial of concurrent and maintenance cediranib in platinum-sensitive relapsed ovarian cancer; the current status is listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: Medical Research Council | Conditions: Ovarian Cancer | Phase 3 | Status: UNKNOWN